SRL
ALLO icon

Scientech Research LLC’s Allogene Therapeutics ALLO Stock Holding History

Scientech Research LLC’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-46,434
Closed -$113K – 241
2026
Q1 		$113K Buy
+46,434
New +$93.1K 0.09% 325
2025
Q4 		– Sell
-26,635
Closed -$33K – 495
2025
Q3 		$33K Buy
+26,635
New +$31.8K 0.01% 524

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Scientech Research LLC's ALLO Position: Q2 2026 in Review

Scientech Research LLC sold out of Allogene Therapeutics (ALLO) in Q2 2026, closing a stake of 46,434 shares — an estimated $113K sold.

Scientech Research LLC first reported a position in ALLO in Q3 2025 and held it in 2 quarters. The position peaked at $113K in Q1 2026. 210 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Scientech Research LLC reported no remaining Allogene Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Scientech Research LLC sold 46,434 Allogene Therapeutics shares in Q2 2026, an estimated $113K.
  • Scientech Research LLC first reported a position in Allogene Therapeutics in Q3 2025 and held it in 2 quarters.
  • Scientech Research LLC's Allogene Therapeutics position peaked at $113K in Q1 2026.
  • 210 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Scientech Research LLC's 13F filing for Q2 2026, filed 14 Aug 2026.